GlassScriptPhysician profile
Eugene J Kim
NPI 1568410827
$1,299.60
in general payments reported to CMS, 2019-2025
19 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $196 · 2022: $146 · 2023: $353 · 2024: $471 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $957.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $460.55 | 2023-2025 | Inspire |
| Resmed Corp | $131.44 | 2024 | |
| Eisai INC. | $116.36 | 2021 | |
| Merck Sharp & Dohme LLC | $97.31 | 2022-2023 | Belsomra |
| Idorsia Pharmaceuticals US INC | $82.13 | 2022-2023 | Quviviq |
| Genzyme Corporation | $50.05 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $41.37 | 2023 | Fasenra |
| Regeneron Healthcare Solutions, INC. | $38.98 | 2021-2023 | Dupixent |
| Jazz Pharmaceuticals INC. | $37.00 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.52 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.86 | 2022 | |
| Glaxosmithkline, LLC. | $31.44 | 2021 | |
| Novartis Pharmaceuticals Corporation | $28.64 | 2022-2023 | |
| Lilly USA, LLC | $24.71 | 2025 | Zepbound |
| Grifols USA, LLC | $22.45 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $19.70 | 2023 | Opsumit, Uptravi |
| Avadel Cns Pharmaceuticals, LLC | $19.05 | 2025 | Lumryz |
| Axsome Therapeutics, INC. | $18.28 | 2023 | Sunosi |
| Teva Pharmaceuticals USA, INC. | $12.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.